Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

AbbVie Receives EC Approval of VENCLYXTO Regimen for Lymphocytic Leukemia

americanpharmaceuticalreviewMarch 16, 2020

Tag: AbbVie , Venclyxto , lymphocytic leukemia , CLL , obinutuzumab

PharmaSources Customer Service